🇺🇸 FDA
Patent

US 11472888

Reelin antibodies for treatment of atherosclerosis

granted A61KA61K2039/505A61K31/713

Quick answer

US patent 11472888 (Reelin antibodies for treatment of atherosclerosis) held by The Board of Regents of the University of Texas System expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K31/713, A61K38/00, A61K45/06